Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients (pts) with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study
Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients (pts) with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective StudyConference abstracts
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: MeganB Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Aspergillus | Leukemia | Myelodysplastic Syndrome | Respiratory Medicine | Study | Websites